NCT00103896|Completed
Connect to Protect Partnerships for Youth Prevention Interventions: Phase II
Connect to Protect (C2P) Partnerships for Youth Prevention Interventions: Phase II
Loading search results
Connect to Protect (C2P) Partnerships for Youth Prevention Interventions: Phase II
Sponsor study identifier
observational
16,706
2 countries
15
Study Start
September 2003
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
October 2010
Actual (reported)Study Completion
October 2010
Actual (reported)This is Phase II of a three stage project whose overall goals are to develop viable community-based HIV prevention interventions and to form and maintain the necessary community collaborations to support such Adolescent Trials Network (ATN) research activities. This phase will describe specific locations within high-risk areas where youth, ages 12-24, spend time. HIV risk behaviors, social networking patterns and HIV prevalence among youth at these venues will be assessed by administering anonymous computerized interviews to eligible and willing youth. This information will be shared with community partners during scheduled working group meetings.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2010
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 2003
Date type not reportedThis date has not been verified as actual or estimated.
February 15, 2005
Actual (reported)February 16, 2005
Actual (reported)October 2010
Actual (reported)October 2010
Actual (reported)Ascertain specific community venues where at-risk youth can be recruited for interventions within the high-risk areas identified in the first Phase of the study
The outcome measure will be assessed using results from: (a) Phase I mapping; (b) Phase II interviews with HIV-infected youth; and (c) Phase II Brief Venue Interviews (BVIs). Input from community partners and ethnographic procedures will add critical information.
One time assessment at 10 months
Describe HIV risk behaviors of adolescents and young adults recruited from targeted venues
The outcome measure will be assessed by conducting HIV serosurveys at each venue identified with youth whose HIV status is unknown.
One time assessment at 10 months
Describe social networks of adolescents and young adults recruited from targeted venues
The outcome measure will be assessed by conducting HIV serosurveys at each venue identified with youth whose HIV status is unknown.
One time assessment at 10 months
Describe HIV seroprevalence of adolescents and young adults recruited from targeted venues
The outcome measure will be assessed by conducting HIV serosurveys at each venue identified with youth whose HIV status is unknown.
One time assessment at 10 months
HIV infected youth in treatment/care will be interviewed using Audio Computer-Assisted Self-Administered Interview ACASI technology to reveal possible venues where youth at high risk for acquiring the disease may be found (N = 20-30 individuals per ATN site).
Additional data will be gathered on potential recruitment venues by administering a brief venue interview (BVI) to individuals who appear to be between 12 and 24 years old (N = unlimited individuals during 3-5 assessment periods per venue each lasting 5 hours).
HIV Serosurvey Individuals Anonymous structured interview using ACASI technology and an anonymous HIV antibody assay will be administered to 20-30 young women at 2-3 targeted locations and 20-30 young men at 2-3 targeted locations whose HIV status is unknown (N = 160-360 individuals per ATN site)..
HIV infected youth, ages 12 through 24 years old, in treatment/care at each of the 15 ATN sites will be interviewed using ACASI technology to reveal possible venues where youth at high risk for acquiring the HIV may be found. Individuals approached at 3-5 of these identified venues who appear to be 12 through 24 years will be offered a brief venue interview. Anonymous HIV serosurvey (ACASI and HIV-Ab assay) will be administered to 20-30 young women at 2-3 identified high-risk venues, and 20-30 young men at 2-3 identified high-risk venues, who provide verbal confirmation of being 12 through 24 years old, and whose HIV status is unknown to the site staff.
Childrens Hospital of Los Angeles
Los Angeles, California, 90054, United States
UCSD Mother, Child & Adolescent HIV Program
San Diego, California, 92103, United States
Univ of Califormia at San Francisco
San Francisco, California, 94143, United States
Children's Hospital National Medical Center
Washington D.C., District of Columbia, 20010, United States
Children's Diag. and Treatment Center
Fort Lauderdale, Florida, 33301, United States
University of Miami
Miami, Florida, 33101, United States
USF Peds Div. of Infectious Disease
Jonathan Ellen, MD
Johns Hopkins Medical Center
Ligia Peralta, MD
Division of Adolescent & Young Adult Medicine University of MD, Medical School
Donna Futterman, MD
Montefiore Medical Center
Marvin Belzer, MD
Childrens Hosp of Los Angeles, Division of Adolescent Medicine
16,706 participants (actual enrollment reported by the registry).
First Submitted
February 15, 2005
First Posted
February 16, 2005
Study Start
September 2003
Date type not reportedThis date has not been verified as actual or estimated.
Healthy Choices to Promote Health and Reduce Risk in HIV-Infected Youth
Assess the characteristics of the community-researcher partnerships
The outcome measure will be assessed by conducting interviews with C2P staff and their community partners. Questionnaires will be completed by both parties and detailed documentation kept.
One time assessment at 10 months
Assess quality of the community-researcher partnerships
The outcome measure will be assessed by conducting interviews with C2P staff and their community partners. Questionnaires will be completed by both parties and detailed documentation kept.
One time assessment at 10 months
Assess outcomes of the community-researcher partnerships
The outcome measure will be assessed by conducting interviews with C2P staff and their community partners. Questionnaires will be completed by both parties and detailed documentation kept.
One time assessment at 10 months
Contact the study team to confirm eligibility.
Tampa, Florida, 33606, United States
Stroger Hospital of Cook County
Chicago, Illinois, 60612, United States
Tulane Medical Center
New Orleans, Louisiana, 70112, United States
University of Maryland
Baltimore, Maryland, 21201, United States
Childrens' Hospital of Boston
Boston, Massachusetts, 02115, United States
Mount Sinai Medical Center
New York, New York, 10128, United States
Montefiore Medical Center, Adolescent AIDS Program
The Bronx, New York, 10467, United States
Children's Hopsital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
University Pediatric Hospital
San Juan, 00936, Puerto Rico
Bret Rudy, MD
Children's Hospital of Philadelphia
Larry D'Angelo, MD
Children's National Research Institute
Cathryn Samples, MD
Boston Children's Hospital
Lisa Henry-Reid, MD
John H. Stroger Jr. Hospital and the CORE Center
Ana Puga, MD
Children's Diag. and Treatment Ctr of Ft. Lauderdale, FL
Lawrence Friedman, MD
University of Miami, School of Medicine, Div of Adolescent Medicine
Patricia Emmanuel, MD
University of South Florida, Peds Div of Infectious Disease
Sue Ellen Abdalian, MD
Tulane Medical Center
Linda Levin, MD
Mount Sinai Adolescent Health Center
Irma Febo, MD
University of Puerto Rico Medical Sciences Campus
Stephen A Spector, MD
UCSD Mother, Child, & Adolescent HIV Program
Rolando M Viani, MD
UCSD Mother, Child, & Adolescent HIV Program
Barbara Moscicki, MD
UCSF, Division of Adoles. Med
Coco Auerswald, MD
UCSF, Division of Adoles. Med
Primary Completion
October 2010
Actual (reported)Study Completion
October 2010
Actual (reported)Last Updated
March 1, 2017
Record last verified: 2016-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: